ArticleThe Psychiatric quarterly2008
'Real world' comparison of first- and second-generation antipsychotics in regard to length of inpatient hospitalization and number of re-hospitalizations.
Article in The Psychiatric quarterly, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this study was to determine if Second-Generation Antipsychotics (SGAs), relative to First-Generation Antipsychotics (FGAs), reduced either the length of stay (LOS) or number of re-hospitalizations of schizophrenic patients receiving treatment in a state psychiatric hospital. Medical records were compared for the periods 1991-1994 and 2001-2004 for three inpatient groups: those receiving FGAs, those receiving SGAs, and those switched from FGAs to SGAs. During both time periods, patients on FGAs had significantly shorter LOS than either those receiving SGAs or those switched from FGAs to SGAs. Therefore, inpatients receiving SGAs were hospitalized longer than those receiving FGAs. Conversely, once discharged, patients receiving SGAs were significantly less likely to be re-admitted than patients discharged on FGAs. The data suggest that some patients do benefit from SGAs and it may be cost-effective in the long-term, to determine when to utilize FGAs first and when to switch from the older to the newer agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.